- Clinical Development
- Therapeutic Expertise
- News & Resources
In early 2013, San Diego-based Synteract acquired Munich-based Harrison Clinical Research, forming SynteractHCR, a top tier international contract research organization. Through our expanded capabilities we support clinical trials globally, handling everything from emerging products through post-marketing. SynteractHCR is a full-service CRO with a successful track record of more than two decades supporting pharmaceutical, biotechnology and medical device companies in all phases of clinical development, across multiple therapeutic areas. We work closely with you to customize programs, using our Intelligent Clinical Development (ICD+) approach to deliver timely, high quality data to help you get to decision points faster.
It’s every biopharma‘s goal – streamlining the drug development process in order to get successful therapies to the patients that need them sooner. SynteractHCR’s smart ICD+ approach helps sponsors do just that. By leveraging our clinical development expertise, technology and execution, we drive solution-oriented efficiencies, globally with a uniform approach to trials to promote consistent standards and high quality.
This is the way we do business, a promised standard that includes ongoing support from a specialized team dedicated to meeting or exceeding your expectations. With our “Shared Work –Shared Vision” philosophy, SynteractHCR provides customized Phase I through IV services collaboratively and cost effectively to ensure on-time delivery of quality data. We have been a trusted clinical trial outsourcing partner to clients for many years, and are proud to have supported over 200 product approvals since 1987. SynteractHCR manages international clinical trials and offers a breadth of therapeutic experience, much of which strategically aligns with the largest areas of clinical R&D investment, including oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory.